WAYNE, Pa., Dec. 14, 2015 /PRNewswire/ -- Bracket, a leading clinical trial specialty services provider, announced this week an important new update to its Randomization and Trial Supply Management product. Mobile patient reminders, delivered via SMS text messaging, are now available as a core component of Bracket's RTSM 4.0 platform.
"Medication and diary compliance is an essential step to executing a successful clinical trial. Expanding the tools available in our platform to ensure patients are taking their medications and reporting their symptoms is another step in our continuing commitment to improving the communication tools available in our eClinical suite," stated Jim Primerano, GM, eClinical, at Bracket.
Bracket SMS allows for reminders to be sent direct to patient mobile phones when they've opted in to the service. Patient information is encrypted and stored safely, and both patients and investigators can opt out of the service at any time. SMS is available globally to any study utilizing Bracket RTSM.
"Investigators and Clinical Trial sites need the right tools to execute research with their patients. Helping them improve medication compliance is one additional feature we include in our platform to help in this mission," stated Jeff Kinell, CEO of Bracket.
About Bracket
Bracket, with seven offices and more than 500 employees worldwide, is a specialty services provider dedicated to helping biopharmaceutical sponsors and contract research organizations increase the power of their clinical research data by leveraging core competencies in Science, Technology, and Service. Bracket eCOA™ is a flexible platform for electronic clinical outcomes assessments. Bracket RTSM™ is a best-in-breed, scalable and configurable clinical IRT solution for the life sciences industry. Bracket Rater Training and Quality Assurance improve outcomes through customized training and quality assurance programs. Learn more about Bracket at https://www.bracketglobal.com/
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.